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REVIEw
the changing Face of Pediatric respiratory
tract Infections: How Human Metapneumovirus
and Human Bocavirus Fit into the overall 
Etiology of respiratory tract Infections in
Young children
Joshua w. Hustedt, BA*, and Marietta Vazquez, MD
Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut
Lower respiratory tract infections are one of the leading causes of morbidity and mortality
in children worldwide. Recent technological advances in the field of molecular biology have
allowed virologists to detect many previously undetected viral pathogens. Two of these,
human metapneumovirus (hMPV†) and human bocavirus (HBoV), are of particular clinical
interest to pediatric health care providers. This review discusses the most common viral
respiratory  infections  in  children,  explores  the  role  of  newly  discovered  respiratory
pathogens, and describes techniques for the diagnosis of viral respiratory infections.
IntroductIon
Lower  respiratory  tract  infections,
commonly caused by viruses [1], are one
of the leading causes of morbidity and mor-
tality in children worldwide. In the United
States, approximately 30,000 children each
year are hospitalized during their first year
of life due to a viral lower respiratory tract
infection [2]. In developing countries, the
problem is even more staggering, where up
to 1.9 million children die each year due to
acute respiratory illnesses [3].
Lower respiratory tract infections are
not only difficult for the patient, but they
can also be difficult for the medical provider
to diagnose [4]. There are many laboratory-
based diagnostic criteria that help physi-
cians determine if an infection is due to
bacterial or viral etiology, a distinction that
guides clinical management of the patient.
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human bocavirus; metapneumovirusBut  even  with  state-of-the-art  diagnostic
tools, there are many cases that are simply
classified as undiagnosable in terms of their
etiology. These cases, hereafter referred to as
undiagnosable respiratory infections, have
caused many researchers to wonder if there
are just many more pathogens out there than
are currently known [5-7]. Recent discover-
ies show that there are new pathogens emerg-
ing  and  that  continuing  research  in
respiratory illnesses is an essential compo-
nent of battling this global issue.  
This review will focus on the role of
newly discovered viruses in lower respira-
tory tract infections in children. The review
will cover an overview of the most common
pediatric  viral  infections,  highlight  ad-
vances in the treatment of these viruses, re-
view  the  laboratory  techniques  for
identifying  newly  discovered  respiratory
viruses  (specifically  human  metapneu-
movirus and human bocavirus), and discuss
the importance of continued research in the
field. Gaining an understanding of respira-
tory tract infections and remaining up-to-
date  on  the  current  discoveries  and
treatments for these illnesses is an impor-
tant responsibility for every pediatric health
care provider.
VIral rEsPIratorY InFEctIons
In cHIldrEn
Until recently, most viral lower respira-
tory infections in children were attributed to
respiratory syncytial virus (RSV), parain-
fluenza  virus,  adenovirus,  and  influenza
viruses [8]. However, two newly discovered
viruses, human metapneumovirus (hMPV)
and human bocavirus (HBoV), have joined
the  list  of  significant  contributors.  Both
viruses, discovered in 2001 and 2005 re-
spectively, constitute up to 13 percent of pre-
viously undiagnosable respiratory infections
in children [9,10]. Additionally, both coron-
avirus and rhinovirus, traditionally regarded
as causes of upper respiratory tract infection,
now have been shown to be present in lower
respiratory  tract  infection  and,  therefore,
should be included in studies looking at all
respiratory tract infections [11].
Identifying the viral etiology of respira-
tory infections in children can be challeng-
ing, especially due to concurrent infections.
A study by Regamey et al. followed 197
children during their first years of life and
found that 122 (62 percent) had at least one
acute respiratory infection in that first year
[12]. Fifteen (17 percent) had dual infections
(infections due to two distinct pathogens),
and three (3 percent) had triple infections.
The findings from Regamey et al. are shown
in Figure 1. Together, rhinoviruses, coron-
aviruses, and the newly discovered hMPV
and  HBoV  accounted  for  49  percent  of
cases, highlighting the role that hMPV and
HBoV play in the etiology of respiratory
tract infections in children. Gaining a better
understanding of these newly discovered
viruses is important in gaining a better un-
derstanding of respiratory infections in chil-
dren.
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Figure 1. This pie chart summa-
rizes the viral etiology findings of a
study published by Regamey et al.
The study followed 197 children
during the first year of life for viral
respiratory infection. One hundred
twenty-two children developed res-
piratory illness during that year.
The pie chart summarizes the etio-
logical cause of the respiratory
symptoms of the 122 children who
developed respiratory tract infec-
tion(s).This review will present a brief overview
of four important viral respiratory pathogens:
RSV, influenza, hMPV, and HBoV.
rEsPIratorY sYncYcIal VIrus
(rsV)
RSV is a member of the Paramyxoviri-
dae family, genus Pneumovirus. RSV is de-
scribed as the single most important viral
pathogen causing acute respiratory infec-
tions in young children. RSV causes illness
in both young infants and in the elderly [13].
In infants, RSV is a common cause of bron-
chiolitis, a lower respiratory tract infection
characterized by wheezing (due to bron-
choconstriction), increased secretions, and
hypoxia. Additional symptoms may include
labored breathing and/or rapid breathing,
cough, stuffy nose, and cyanosis (bluish tint
to the skin due to lack of oxygen). Serolog-
ical evidence shows that almost all children
are exposed to RSV during the first three
years of life [14]. However, previous infec-
tion does not prevent subsequent infections,
and repeat infections are common in all age
groups. Peak infection rates occur in infants
aged 6 weeks to 6 months.
RSV takes a heavy toll on infants each
year, with up to 500 deaths in the United
States [15]. Infants who are younger than 3
months or have a history of premature birth,
bronchopulmonary dysplasia, congenital heart
disease, cystic fibrosis, or immunosuppression
are more pre-disposed to RSV infection.
Treatment for RSV remains controversial
[16]. Available treatments include beta-ago-
nists, corticosteroids, racemic epinephrine,
and ribavirin (an anti-viral medication used to
suppress  RSV  viral  replication).  Beta-ag-
noists, corticosteroids, and racemic epineph-
rine all target the symptoms of bronchiolitis,
with the end goal of dilating the airway and
decreasing secretions to allow for adequate
oxygen exchange in the lungs. Ribavirin is a
seldom-used anti-viral medication that targets
RSV viral replication. The end goal of Rib-
avirin treatment is to decrease the amount of
virus in the affected tissue, reducing the virus’
ability to cause disease. However, in a sys-
tematic review by King et al., the authors re-
port that none of the above mentioned med-
ications significantly improve clinical out-
comes compared to supportive therapy, such
as hydration and oxygenation [17].
Currently, no vaccine is available to
prevent RSV infection, but several vaccine
candidates are in the early stages of clinical
trials [18]. Preventive measures include the
use of a humanized monoclonal antibody,
Palivizumabﾮ, which has been shown to
significantly decrease infection in high-risk
children when given as prophylaxis during
RSV season [19]. Palivizumab’s beneficial
effects are due to its role as a monoclonal
antibody (IgG) directed against the A anti-
genic site of the F protein of RSV. It is ad-
ministered via intramuscular injection and
prevents viral infection by binding the virus
in situ. While this treatment is effective, it is
expensive and reserved for those at high
risk, such as premature infants. 
InFluEnza
Influenza viruses are a group of viruses
in the Orthomyxoviridae family. While in-
fluenza is commonly referred to as the “flu,”
influenza is actually a group of viruses in
three genuses: Influenza A, Influenza B, and
Influenza C. Influenza A is further classified
by hemagglutinin (H) and neuraminidase
(N) sub-types. For example, the 2009 global
pandemic of swine flu was due to influenza
A, type H1N1. Infection by Influenza B pro-
duces a less serious disease, while Influenza
C  is  not  known  to  cause  epidemics.  In-
fluenza A and Influenza B are important
causes of respiratory tract infection in chil-
dren  of  all  ages.  Common  symptoms  of
these  viruses  include  fever,  cough,  sore
throat,  runny  or  stuffy  nose,  headache,
chills, muscle aches, and, in children, even
diarrhea and vomiting.
During the 2009 influenza season, 269
children  younger  than  18  died  from  in-
fluenza-related symptoms. Approximately
70 percent of the deaths occurred in children
with underlying medical conditions, but 30
percent of the deaths occurred in previously
healthy children [20]. Vaccines have been
successful in reducing morbidity and mor-
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influenza infections each year, in part due to
the fact that different strains of influenza are
prevalent every year.  
The American Academy of Pediatrics
(AAP) and the U.S. Center for Disease Con-
trol’s Advisory Committee on Immunization
Practices (ACIP) currently recommend that
all children older than 6 months receive the
influenza vaccine each year [21]. Recent
studies also have suggested that giving the
vaccine to pregnant mothers offers protec-
tion  to  the  newborn  during  the  first  six
months of life, presumably via passive trans-
fer of immunity from the mother [22,23].
Treatment for influenza includes four
currently available anti-viral medications:
amantadine, rimantadine, anamivir, and os-
eltamivir  [16].  Oseltamivir  (trade  name
Tamifluﾮ) and zanamivir (trade name Re-
lenzaﾮ) are neuraminidase inhibitors that
are often effective against Influenza A and
B. Neuraminidase inhibitors block the neu-
raminidase  enzyme  that  cleaves  budding
viral progeny just prior to release, therefore
effectively blocking viral replication. Aman-
tadine  (trade  name  Symmetrelﾮ)  and  ri-
mantadine (trade name Flumadineﾮ) target
a viral ion channel necessary in the uncoat-
ing process of Influenza A, thereby prevent-
ing  the  virus  from  infecting  host  cells.
Amantadine and rimantadine are effective
against Influenza A only and reach maxi-
mum benefit when begun early in infection.
Influenza viruses have a high rate of muta-
tion, and anti-viral resistance has been an
ongoing issue with the development of in-
fluenza anti-viral medications. The CDC
provides recommendations on the use of
anti-virals to minimize the risk of viral re-
sistance to the medications and currently
only recommends the use of oseltamivir and
zanamivir for treatment in the United States.
Influenza anti-virals are most effective
when started early in infection (within 48
hours) [24]. The AAP recommends antiviral
treatment be considered in any child with in-
fluenza who is also at high risk of influenza
complications, regardless of vaccination sta-
tus, and any otherwise healthy child with
moderate-to-severe influenza infection who
might benefit from the decrease in duration of
clinical symptoms documented to occur with
antiviral therapy [25]. However, the use of in-
fluenza anti-virals is always a clinical balanc-
ing act, as the anti-virals are expensive, have
side effects (such as headache, sore throat,
nausea, vomiting, and, rarely, allergic reac-
tion), and the overuse of the medications can
lead to influenza strains resistant to anti-virals. 
HuMan MEtaPnEuMoVIrus
In June 2001, researchers in the Nether-
lands identified a new respiratory pathogen
isolated from respiratory secretions in chil-
dren with respiratory tract disease [26]. Fur-
ther analysis showed the new pathogen to be
a paramyxovirus, the first known non-avian
pathogen of the Metapneumovirus genus.
This  new  pathogen,  termed  hMPV,  was
found to be closely related to RSV.
Esper et al. showed that hMPV is a sig-
nificant contributor to respiratory illnesses in
children, responsible for up to 8 percent of
previously undiagnosable viral respiratory
infections [9]. The clinical presentation of
hMPV is similar to that of other respiratory
viruses, such as the closely associated RSV.
Both upper and lower respiratory tract infec-
tions  have  been  shown  to  be  caused  by
hMPV. Clinical symptoms include coughing,
wheezing, hypoxia, and fever [27]. Infection
occurs in all age groups, but young children
and the elderly are most commonly affected.
Serological studies have been under-
taken to examine the extent of hMPV in the
general population and have shown that al-
most all people are infected with hMPV by
the age of 5 [28]. For most, the symptoms
are similar to a mild cold. Yet in some chil-
dren, hMPV can be the cause of severe res-
piratory infection requiring hospitalization
due to respiratory failure.  
hMPV appears to have a seasonal dis-
tribution,  with  most  infections  occurring
during the winter and spring [29]. There are
no antiviral treatments for hMPV infection
currently available or in clinical trials. Treat-
ment options include supportive care for res-
piratory  infections,  bronchodilators,  and
inhaled corticosteroids.  
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HBoV is a parvovirus first described in
2005 by Allander and colleagues in respira-
tory samples from Sweden [30]. Allander’s
research team identified HBoV by random
polymerase chain reaction (PCR) analysis of
samples from patients with pneumonia. The
team identified a parvovirus-like sequence by
sequencing all possible DNA/RNA material
in the samples and comparing them to known
viral, bacterial, and human sequences. Phy-
logenetic analysis showed that this novel par-
vovirus was most closely related to bovine
parvovirus and a canine minute virus. The
only other known parvovirus with clinical
implications is parvovirus B19, which causes
fifth disease or erythema infectiosum (a com-
mon rash of childhood) and can have serious
complications such as aplastic crisis in he-
molytic syndromes (such as sickle cell dis-
ease) and hydrops fetalis in fetuses.  
HBoV is a small, but significant contrib-
utor to respiratory tract infections in children.
In a study at Yale University, researchers ex-
amined  respiratory  isolates  from  children
with respiratory illness that were negative for
all other known viral pathogens. Of these pre-
viously undiagnosable specimens, 5.2 percent
tested positive for HBoV [10]. In serological
studies, researchers have found that almost all
children are exposed to HBoV by the time
they are 5 years old [31,32]. 
HBoV infection is clinically similar to
other respiratory virus infections. Common
symptoms include fever, rhinorrhea, cough,
and wheezing [10]. To date, there are no
medications available or in clinical trials for
HBoV. Mainstays of treatment include sup-
portive care, inhaled bronchodilators, and
corticosteroids.  
MEtHods to IdEntIFY tHE
VIrusEs causIng InFEctIon
Rapid Diagnosis
Rapid diagnoses of viral infections can
be obtained using immunofluorescence and
PCR  techniques.  Direct  immunofluores-
cence assays, which utilize an antibody la-
beled  with  an  immunofluorescent  tag  to
identify the presence of live virus in a sam-
ple, can offer a rapid diagnosis. Direct im-
munofluorescence  tests  generally  have  a
sensitivity of 95 percent to 100 percent [33].
The  advent  of  PCR  has  greatly  en-
hanced identification and classification of
viruses. PCR has proven to be a very sensi-
tive and specific method for the detection of
respiratory viruses [34], and the recent de-
velopment of real-time PCR has allowed
PCR to be used in rapid diagnostics.
Serological Diagnosis and Viral Culture
Serological diagnosis can be performed
using  an  enzyme-linked  immunosorbent
assay (ELISA). An ELISA can identify anti-
bodies in human serum against a specific
virus and can be used to detect current in-
fection as well as past viral exposure. Al-
though  viral  culture  remains  the  gold
standard for viral detection, PCR and newer
technologies in molecular biology are likely
to replace viral culture in the future. Many
laboratories will run a rapid diagnostic test
and follow up with viral culture.
HuMan MEtaPnEuMoVIrus
hMPV PCR
hMPV has five main viral genes that can
be identified by PCR: the nucleoprotein (N),
phosphoprotein (P) matrix (M), fusion (F),
and polymerase (L). hMPV is difficult to
grow in culture, so PCR is the predominant
method used to detect the virus. In a compar-
ative evaluation of Real-Time PCR Assays,
Cot￩ and colleagues found that the N and L
genes, which code for two internal hMPV
viral proteins, were most suitable for hMPV
diagnosis. The sequences for the primers used
can be found in their paper [35].
hMPV ELISA
An hMPV ELISA technique was devel-
oped at Yale University by Leung et al [28].
These researchers cloned the fusion (F) gene
of  hMPV  into  vesicular  stomatitis  virus
(VSV), and then infected BHK or HEp-2
(human larynx carcinoma cells) with the
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ple rounds of replication in the BHK cells,
the VSV-hMPV F viral construct was re-
moved and purified to be plated as antigen in
an ELISA assay. The ELISA assay was used
to detect antibody to hMPV from human
serum. A more detailed explanation of their
techniques, along with sequences for viral
primers can be found in their paper [28].
HuMan BocaVIrus
HBoV PCR
Allander et al. included the protocol for
PCR and sequence for HBoV primers in
their  paper  [30].  Forward  and  reverse
primers along with PCR protocol to target a
portion of the HBoV NP-1 gene are pub-
lished by Kahn et al [31]. The primers can
also be accessed on GenBank.
HBoV ELISA
A HBoV specific ELISA was developed
by Kahn et al. at Yale University using virus-
like particles (VLP) [31]. Nucleic acids from
a respiratory specimen positive for HBoV by
PCR were extracted, and the HBoV VP2
gene was amplified and cloned sequentially
into a pFastBac vector (Invitrogen). A re-
combinant baculovirus was generated using
the Bac-to-Back Expression System (Invit-
rogen)  by  transforming  into  competent,
bacmid-containing DH10 E. coli cells and
transfection of the high-molecular-weight
DNA  that  this  generated  into  Sf9  insect
cells.  The  resulting  baculovirus  was  ex-
panded and then titered by plaque assay on
Sf9 monolayer cultures and plated on a 96-
well  plate  for  use  in  the  ELISA  assay.
Human serum from patients was used as pri-
mary antibody in the ELISA assay to screen
for antibodies to HBoV.
conclusIon
Recent developments in biotechnology
have allowed research scientists to identify
many new respiratory viruses. Two of these,
hMPV and HBoV, account for a significant
portion of previously undiagnosable respi-
ratory infections. The current advances in
laboratory techniques are important for cli-
nicians, who must be up to date on current
treatment and diagnostics in respiratory in-
fections. Pediatricians must pay particular
attention due to the high morbidity and mor-
tality caused by respiratory infections in
children.
Viral respiratory infections continue to
be a worldwide health issue. Scientific ad-
vances in the field have increased diagnos-
tics and treatment. Studies suggest there
may be more viruses yet to be discovered [5-
7]. Additional research into understanding
these viruses and the developments of vac-
cines for viral respiratory infections will
prove to be essential for fighting this world-
wide health issue.  
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